Explore our list of non-proprietary assays
Aliri brings more than 30 years of experience in bioanalytical services, developing robust methods to support all stages of drug discovery and development. We offer an extensive list of validated, off-the-shelf assays you can leverage to support a range of research applications. In addition to the hundreds of assays listed below, Aliri also excels at developing customized methods to meet your specific challenges.
Please contact us with any questions or if your compound is not on this list.
Contact us
| Compound(s) | Species Matrix | Validated Range | Anticoagulant (s) |
|---|---|---|---|
| Abacavir | Human Plasma | 10.0–2,000 ng/mL | K2EDTA |
| Abiraterone | Human Plasma | 0.200–200 ng/mL | K2EDTA |
| Acetaminophen | Human Dried Blood Spot | 50.0–30,000 ng/mL | Sodium Heparin |
| Acetaminophen | Human Plasma | 50.0–30,000 ng/mL | Sodium Heparin |
| Acetaminophen | Human Urine | 1.00–250 µg/mL | NA |
| Albuterol | Human Plasma | 1.00–1,000 pg/mL | K2EDTA |
| Amprenavir | Human Plasma | 10.0–10,000 ng/mL | K2EDTA /K3EDTA |
| Apixiban | Human Plasma | 5.00–1,000 ng/mL | K2EDTA |
| Aripiprazole | Human Plasma | 1.00 - 1,000 ng/mL | K3EDTA |
| Atazanavir | Human Plasma | 1.00–1,000 ng/mL | K3EDTA |
| Atazanavir | Human Plasma | 10.0–5,000 ng/mL | K2/K3EDTA |
| Atazanavir | Human Plasma | 25.0–5,000 ng/mL | K2EDTA |
| Atazanavir | Human Plasma | 10.0–10,000 ng/mL | K2EDTA |
| ATRIPLA™ (Tenofovir, Emtricitabine, Efavirenz) | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
| Bortezomib | Human Plasma | 0.500–500 ng/mL | Sodium Heparin |
| Budesonide | Human Plasma | 3.00–300 pg/mL | EDTA |
| Budesonide | Human Plasma | 10.0–5,000 pg/mL | K2EDTA |
| Buprenorphine | Human Plasma | 25.0–10,000 pg/mL | K2EDTA |
| Buprenorphine | Human Plasma | 0.0500–20.0 ng/mL | K3EDTA |
| Bupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Bupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Bupropion, Hydroxybupropion | Human Plasma | 0.0500–2,500 ng/mL | K2EDTA |
| Bupropion/ Hydroxybupropion/ Erythrohydrobupropion / Threohydrobupropion | Human Plasma | 1.00–1,000 ng/mL | Sodium Heparin |
| Capecitabine | Human Plasma | 10.0–1,000 ng/mL | K2EDTA |
| Capsaicin | Human Plasma | 0.0500–50.0 ng/mL | K2EDTA |
| Carbamazepine | Human Plasma | 50-50,000 ng/mL | K2EDTA |
| Clarithromycin | Human Plasma | 5.00 - 5,000 ng/mL | K3EDTA |
| Clindamycin | Human Plasma | 50–50,000 ng/mL | K2EDTA |
| Coproporphyrin I and Coproporphyrin III | Human Plasma | 50-5,000 pg/mL | K2EDTA |
| Cortisol | Human Urine | 1.00 to 100 ng/mL | NA |
| Cortisol / 6beta-hydroxycortisol | Human Urine | 1.00–400 ng/mL for Cortisol 2.50–1,000 ng/mL for 6beta-hydroxycortisol | NA |
| Cyclophosphamide | Human Plasma | 20.0–10,000 ng/mL | K2EDTA |
| Cyclosporin A | Human Whole Blood | 5.00–2,000 ng/mL | K2EDTA /K3EDTA |
| Cyclosrporine | Human Whole Blood | 2.00–2,000 ng/mL | K2EDTA |
| Darunavir | Human Plasma | 20.0–4,000 ng/mL | K2EDTA |
| Darunavir | Human Plasma | 10.0–10,000 ng/mL | K2EDTA |
| Dexamethasone | Human Plasma | 0.250–250 ng/mL | K2EDTA |
| Dextromethorphan | Human Plasma | 1.00–500 ng/mL | K2EDTA |
| Dextromethorphan | Human Urine | 1.00–500 ng/mL | NA |
| Dextromethorphan | Human Urine | 1.00–500 ng/mL | NA |
| Dextrorphan | Human Urine | 50.0–25,000 ng/mL | NA |
| Dextrorphan | Human Plasma | 1.00–500 ng/mL | K2EDTA |
| Dextrorphan | Human Urine | 1.00–500 ng/mL | NA |
| Diclofenac | Human Plasma | 0.100–100 ng/mL | NaHep |
| Diclofenac | Human Plasma | 10.00–2,000 ng/mL | K2EDTA |
| Digoxin | Human Plasma | 100–50,000 pg/mL | K2EDTA |
| Digoxin | Human Urine | 1.00–100 ng/mL | NA |
| Docetaxel | Human Plasma | 10.0–10,000 ng/mL | K2EDTA /K3EDTA |
| Doxorubicin | Human Plasma | 5.00–1,000 ng/mL | K2EDTA |
| Doxorubicin / Doxorubicinol | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
| Doxorubicinol | Human Plasma | 2.00–400 ng/mL | K2EDTA |
| Efavirenz | Human Plasma | 10.0–2,000 ng/mL | K2EDTA |
| Efavirenz | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
| Emtricitabine | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
| Emtricitabine | Human Plasma | 5.00–3,000 ng/mL | K2EDTA |
| Entecavir | Human Plasma | 0.0400–16.0 ng/mL | K2EDTA |
| Erythrohydrobupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Erythrohydrobupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Esomeprazole | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
| Eszopiclone | Human Plasma | 1.00–100 ng/mL | K3EDTA |
| Etravirine | Human Plasma | 2.00–400 ng/mL | K2EDTA |
| Everolimus | Human Whole Blood | 0.200–50.0 ng/mL | K2EDTA |
| Famotidine | Human Plasma | 1.00–500 ng/mL | K3EDTA |
| Famotidine | Human Plasma | 1.00–500 ng/mL | K3EDTA |
| Fluconazole | Human Plasma | 100–10,000 ng/mL | K3EDTA |
| Fluconazole | Human Plasma | 20.0–10,000 ng/mL | K2EDTA |
| Fluoxetine | Human Plasma | 0.100–50.0 ng/mL | K2EDTA |
| Fluticasone propionate | Human Plasma | 5.00–1,000 pg/mL or 5.00–500 pg/mL | K3EDTA |
| Fluticasone propionate | Human Plasma | 1.00–200 pg/mL | K2EDTA |
| Fluticasone propionate | Human Plasma | 3.00–300 pg/mL | K2EDTA |
| Formoterol | Human Plasma | 1.00–100 pg/mL | EDTA |
| Formoterol | Human Plasma | 1.00–100 pg/mL | K3EDTA |
| Furosemide | Human Plasma | 10.0–10,000 ng/mL | K2EDTA |
| Gemfibrozil | Human Plasma | 50.0 - 25,000 ng/mL | Sodium Heparin |
| Guanfacine | Human Plasma | 0.0500–5.00 ng/mL | K2EDTA |
| Hydrochlorothiazide | Human Plasma | 1.00–200 ng/mL | K2EDTA |
| Hydroxybupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Hydroxybupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Ibandronate | Human Plasma | 0.100–50.0 ng/mL | K2EDTA |
| Ibandronate | Human Plasma | 0.200–200 ng/mL | K2EDTA |
| Iohexol | Human Plasma | 1.00–500 μg/mL | K2 EDTA |
| Iohexol | Human Urine | 2.00–1,000 μg/mL | NA |
| Irinotecan / SN-38 | Human Plasma | 5.00–2,500 ng/mL for Irinotecan and 1.00–500 ng/mL for SN-38 | K2EDTA |
| Itraconazole | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Itraconazole / Hydroxy Itraconazole | Human Plasma | 2.00–1,000 ng/mL | K2EDTA |
| Ketoconazole | Human Plasma | 50.0–5,000 ng/mL | Sodium Heparin |
| Ketoconazole | Human Plasma | 50.0–5,000 ng/mL | K2EDTA |
| Ketoconazole | Human Plasma | 50.0–5,000 ng/mL | K2EDTA |
| Ketoconazole | Human Plasma | 20.0–10,000 ng/mL | K2EDTA |
| Lamivudine | Human Plasma | 10.0–2,000 ng/mL | K2EDTA |
| Lanreotide | Human Plasma | 0.300-100 ng/mL | K2EDTA |
| Lenalidomide | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Levonorgestrel | Human Plasma | 25-10,000 pg/mL | K2EDTA |
| Lopinavir | Human Plasma | 5.00–5,000 ng/mL | K2EDTA /K3EDTA |
| Losartan / Losartan Carboxylic Acid | Human Plasma | 1.00–1,500 ng/mL | K2EDTA |
| LTE4 | Human Urine | 2.00–500 pg/mL | NA |
| Maraviroc | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Mefenamic acid | Human Plasma | 50.0–5,000 ng/mL | K3EDTA |
| Memantine | Human Plasma | 0.100–100 ng/mL | K3EDTA |
| Mesalamine | MeCN Ext from HuP | 2.00–2,000 ng/mL | K2EDTA |
| Metformin | Human Plasma | 10-3,500 ng/mL | K2EDTA |
| Methadone/EDDP | Human Plasma | 0.200–400 ng/mL | K2EDTA |
| Methadone/EDDP | Human Urine | 0.200–400 ng/mL | NA |
| Methotrexate | Human Plasma | 1.00–500 ng/mL | NaEDTA |
| Methotrexate / 7-Hydroxymethotrexate | Human Plasma | 1.00–500 ng/mL | K2EDTA |
| Methotrexate / 7-Hydroxymethotrexate | Human Urine | 1,000–50,000 ng/mL / 50.0–2,500 ng/mL | NA |
| Methyl-Prednisolone | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Midazolam / 1-Hydroxymidazolam | Human Plasma | 0.200–10.0 ng/mL | EDTA/Lithium Heparin |
| Midazolam / 1-Hydroxymidazolam | Human Plasma | 0.100–10.0 ng/mL | Na2EDTA |
| Midazolam / 1-Hydroxymidazolam | Human Plasma | 0.200–10.0 ng/mL | K2EDTA |
| Midazolam and Fexofenadine | Human Plasma | 0.100–300 ng/mL 2.00–6,000 ng/mL | K2EDTA |
| Midazolam and α-Hydroxymidazolam | Human Plasma | 0.100–100 ng/mL | K2EDTA |
| Moexipril | Human Plasma | 1.00–200 ng/mL | K2EDTA |
| Montelukast and Montelukast 1,2-diol | Human Plasma | 5.00–1,000 ng/mL | K2EDTA |
| Morphine | Human Plasma | 0.500–100 ng/mL | K2EDTA |
| Morphine / Morphine-3β-D-glucuronide / Morphine-6β-D-glucuronide | Human Plasma | 0.500–50.0 ng/mL / 10.0–1,000 ng/mL / 1.00–100 ng/mL | K2EDTA |
| Morphine-6-β-D-glucuronide | Human Plasma | 2.50–500 ng/mL | K2EDTA |
| Moxifloxacin | Human Plasma | 25.0–5,000 ng/mL | K2EDTA |
| Moxifloxacin | Human Plasma | 25.0–5,000 ng/mL | NaHep |
| Moxifloxacin | Human Plasma | 25.0–5000 ng/mL | Sodium Heparin |
| Mycophenolic acid | Human Plasma | 2.50–2500 ng/mL | K2EDTA |
| Mycophenolic acid-β-D-Glucuronide | Human Plasma | 25.0–25,000 ng/mL | K2EDTA |
| Naloxone | Human Plasma | 0.00500–2.00 ng/mL | K3EDTA |
| Naltrexone / Naltrexol | Human Plasma | 0.0200–2.00 ng/mL / 0.500–50.0 ng/mL | K2EDTA |
| Nelfinavir | Human Plasma | 1.00–1,000 ng/mL | K2EDTA /K3EDTA |
| Nevirapine | Human Plasma | 20.0–4,000 ng/mL | K2EDTA |
| Nifedipine | Human Plasma | 1.00–250 ng/mL | K2EDTA |
| Nilotinib | Human Plasma | 5.00–2,000 ng/mL | K2EDTA |
| Nisoldipine | Human Plasma | 50.0–10,000 pg/mL | K2EDTA |
| Norbuprenorphine | Human Plasma | 50.0–20,000 pg/mL | K2EDTA |
| Norbuprenorphine | Human Plasma | 0.100–40.0 ng/mL | K3EDTA |
| Norethindrone/Ethinyl Estradiol | Human Plasma | 50.0–15,000 pg/mL 5.00–1,500 pg/mL | K2EDTA |
| Norfluoxetine aka Seproxetine | Human Plasma | 0.100–50.0 ng/mL | K2EDTA |
| Octreotide | Human Plasma | 0.0500–20.0 ng/mL | K2EDTA |
| Octreotide | Human Plasma | 0.100-100 ng/mL | K2EDTA |
| Olanzapine | Human Plasma | 0.250–100 ng/mL | K2EDTA |
| Omeprazole | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Omeprazole / 5-Hydroxy Omeprazole | Human Plasma | 10.0–1,000 ng/mL | K2EDTA /K3EDTA |
| Paclitaxel | Human Plasma | 10.0–2,000 ng/mL | K3EDTA |
| Pitavastatin | Human Plasma | 0.101-202 ng/mL | K2EDTA |
| Pramipexole | Human Plasma | 50.0–5,000 pg/mL | K3EDTA |
| Pramipexole | Human Plasma | 25.0–2,500 pg/mL | K2EDTA /K3EDTA |
| Pravastatin | Human Plasma | 0.250-250 ng/mL | K2EDTA |
| Prednisone | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Pregabalin | Human Plasma | 50.0–20,000 ng/mL | K2EDTA |
| Prenisolone | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| R,S-Methadone | Human Plasma | 0.500–100 ng/mL | K3EDTA |
| R,S-Methadone | Human Plasma | 5.00–1,000 ng/mL | K2EDTA /K3EDTA |
| Raltegravir | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Raltegravir | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Raltegravir II | Human Plasma | 10.0–10,000 ng/mL | K2EDTA |
| Ramelteon | Human Plasma | 0.0500–8.00 ng/mL | K2EDTA |
| Repaglinide | Human Plasma | 0.200-200 ng/mL | K2EDTA |
| Ribavirin | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
| Rifampin | Human Plasma | 50.0–35,000 ng/mL | K2EDTA and Sodium Fluoride/Potassium Oxalate |
| Rifampin | Human Plasma | 100–10,000 ng/mL | K2EDTA |
| Rifaximin | Human Plasma | 0.100–10.0 ng/mL | K2EDTA |
| Rilpivirine | Human Plasma | 1.00–500 ng/mL | K2EDTA |
| Riluzole | Human Dried Blood Spot | 5.00–2,000 ng/mL | K2EDTA |
| Riluzole | Human Plasma | 5.00–2,000 ng/mL | K2EDTA /K3EDTA |
| Risperidone / 9-Hydroxyrisperidone | Human Plasma | 0.200–100 ng/mL | K2EDTA |
| Ritonavir | Human Plasma | 1.00–1,000 ng/mL | K3EDTA |
| Ritonavir | Human Plasma | 5.00–5,000 ng/mL | K2EDTA /K3EDTA |
| Ritonavir | Human Plasma | 10.0–5,000 ng/mL | K2EDTA /K3EDTA |
| Rosiglitazone | Human Plasma | 1.00–1,000 ng/mL | K2EDTA /K3EDTA |
| Rosuvastatin | Human Plasma | 0.100–100 ng/mL | K2EDTA |
| Rosuvastatin / Desmethyl Rosuvastatin / Rosuvastatin Lactone | Human Plasma | 0.0200–20.0 ng/mL for Rosuvastatin 0.100–10.0 ng/mL for Desmethyl Rosuvastatin 0.0500–10.0 ng/mL for Rosuvastatin Lactone | K2EDTA |
| R-Warfarin | Human Plasma | 10.0–2,500 ng/mL | K2EDTA |
| Salmeterol | Human Plasma | 2.50–500 pg/mL | K3EDTA |
| Salmeterol | Human Plasma | 1.00–100 pg/mL | K2EDTA |
| Salmeterol | Human Plasma | 1.00–200 pg/mL | K2EDTA |
| Saquinavir | Human Plasma | 2.00–400 ng/mL | K2EDTA |
| Scopolamine | Human Plasma | 0.00200–2.00 ng/mL | K2EDTA |
| Sertraline / N-desmethylsertraline | Human Plasma | 0.250–100 ng/mL for Sertraline 0.500–100 ng/mL for N-desmethylsertraline | Sodium Heparin |
| Sildenafil and N-desmethyl sildenafil | Human Plasma | 0.500–500 ng/mL | K2EDTA |
| Sirolimus (rapamycin) | Human Plasma | 0.100-100 ng/mL | K2EDTA |
| Stavudine | Human Plasma | 5.00–1,000 ng/mL | K2EDTA |
| S-Warfarin | Human Plasma | 10.0–2,500 ng/mL | K2EDTA |
| Tacrolimus | Human Whole Blood | 50.0–10,000 pg/mL | K2EDTA |
| Tacrolimus | Whole Blood | 0.100–100 ng/mL | K2EDTA |
| Tadalafil | Human Plasma | 1.00–500 ng/mL | K3EDTA |
| Telmisartan | Human Plasma | 0.500–5,000 ng/mL | K3EDTA |
| Temozolomide | Human Plasma | 100–20,000 ng/mL | K2EDTA |
| Tenofovir | Human Plasma | 5.00–3,000 ng/mL | K2EDTA |
| Tenofovir | Human Plasma | 1.00–500 ng/mL | K2EDTA /K3EDTA |
| Tranexamic acid | Human Plasma | 50-12000 ng/mL | K2EDTA |
| Threohydrobupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Threohydrobupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Tiotropium | Human Plasma | 1.00–500 pg/mL | K2EDTA |
| Tiotropium | Human Plasma | 0.500–500 pg/mL | K2EDTA |
| Tolbutamide / 4-hydroxytolbutamide | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
| Total 4-beta hydroxycholesterol | Human Plasma | 4.00–400 ng/mL | K2EDTA |
| Total cholesterol | Human Plasma | 500–5,000 μg/mL | K2EDTA |
| Tramadol | Human Plasma | 1.00–500 ng/mL | K2EDTA |
| Valproic acid | Human Plasma | 0.200–100 μg/mL | K2EDTA |
| Valproic Acid aka valproate | Human Serum | 1–100 μg/mL | NA |
| Valsartan | Human Plasma | 50.0–10,000 ng/mL | K2EDTA /K3EDTA |
| Vardenafil | Human Plasma | 0.200–50.0 ng/mL | K2EDTA /K3EDTA |
| Vincristine | Human Plasma | 0.500–100 ng/mL | K2EDTA |
| Voriconazole | Human Plasma | 5.00–5,000 ng/mL | K2EDTA /K3EDTA |
| Warfarin (R-) / Warfarin (S-) | Human Plasma | 10.0–1,000 ng/mL | K3EDTA |
| Zidovudine | Human Plasma | 4.00–800 ng/mL | K2EDTA |
| 4-beta Hydroxycholesterol | Human Plasma | 4.00–400 ng/mL | K2EDTA |
| Atorvastatin, para-Hydroxy Atorvastatin and ortho-Hydroxy Atorvastatin | Human Plasma | 0.300–50.0 ng/mL | K2EDTA |
| Aldosterone | Human Plasma | 10.0–5,000 pg/mL | K2EDTA |
| Aldosterone | Human Urine | 0.200–200 ng/mL | K2EDTA |
| Bile Acids (11 acids) | Human Plasma | 2.00–1,000 ng/mL/ 1.00–500 ng/mL/ 5.00–2,500 ng/mL | K2EDTA |
| Salicylic Acid and Acetylsalicylic Acid | Human Plasma | 25.0–25,000 ng/mL | Sodium Fluoride/Potassium Oxalate |
| Thromboxane B2 | Human Serum | 1.00–500 ng/mL | NA |
| Total Dabigatran | Human Plasma | 1.10–550 ng/mL | K2EDTA |
| Dabigatran | Human Plasma | 1.10–550 ng/mL | K2EDTA |
| Irbesartan | Human Plasma | 10.0–10,000 ng/mL | K2EDTA |
| Letrozole | Human Plasma | 0.500–250 ng/mL | K2EDTA |